Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions - 06/04/16
Abstract |
Background |
The optimal approach to patients with hypersensitivity reactions (HSRs) to taxanes has not been established.
Objective |
We sought to assess the safety and efficacy of risk stratification based on the severity of the initial HSR and skin testing for guiding taxane reintroduction in patients with an HSR to these agents.
Methods |
Data on 164 patients treated for a taxane-related HSR from April 2011 to August 2014 at the Dana-Farber Cancer Institute and Brigham and Women's Hospital were collected retrospectively. Patients were re-exposed to taxanes either through desensitization, challenge, or regular infusion based on the severity of the initial HSR and skin test response. Depending on the initial risk stratification and tolerance to re-exposure, patients were then treated with shorter desensitization protocols, challenge, or both with the aim of resuming regular infusions, except in patients with a severe immediate initial HSR.
Results |
Of 138 patients desensitized, 29 (21%) had an immediate and 20 (14%) had a delayed HSR with the procedure. Of 49 patients challenged, 2 (4%) had a mild immediate and 1 (2%) had a delayed HSR with the procedure. No patients had a severe immediate HSR with desensitization or challenge. Thirty-six (22%) patients eventually resumed regular infusions. These patients were more likely to have negative skin test responses and to have experienced a delayed or mild immediate initial HSR.
Conclusions |
Risk stratification based on the severity of the initial HSR and skin testing to guide taxane reintroduction is safe and allows a significant number of patients to resume regular infusions.
Le texte complet de cet article est disponible en PDF.Key words : Taxane, paclitaxel, docetaxel, hypersensitivity, skin test, allergy, risk stratification, desensitization, challenge
Abbreviations used : BWH, DFCI, HSR, nab-paclitaxel, OR, ST+, ST−
Plan
| Supported by Ovations for the Cure of Ovarian Cancer. |
|
| Disclosure of potential conflict of interest: M. Picard serves as a consultant for Algorithme Pharma and receives payment for lectures from Sanofi. S. T. Berlin receives payment for lectures related to Ovarian Cancer Support Group and Ethic Curriculum Development. M. C. Castells received travel support from the ECNM, NJAIS, ACAAI, and AAAAI; serves on the board of the AAMC; and serves as a consultant for Merck, Sanofi, Neurophyne, Melbourne Allergies Therapeutic, and Brigham and Women's Hospital. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 137 - N° 4
P. 1154 - avril 2016 Retour au numéro
Article précédent
- Consequences of avoiding ?-lactams in patients with ?-lactam allergies
- Meghan N. Jeffres, Prasanna P. Narayanan, Jerrica E. Shuster, Garrett E. Schramm
- Chediak-Higashi syndrome: Lysosomal trafficking regulator domains regulate exocytosis of lytic granules but not cytokine secretion by natural killer cells
- Aleksandra Gil-Krzewska, Stephanie M. Wood, Yousuke Murakami, Victoria Nguyen, Samuel C.C. Chiang, Andrew R. Cullinane, Giovanna Peruzzi, William A. Gahl, John E. Coligan, Wendy J. Introne, Yenan T. Bryceson, Konrad Krzewski
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?